View abstract

Cet abstract a été assigné à session AOB Free papers
TitreDoes generic Latanoprost measure up to the branded, well-known Xalatan® ?
Abstract Nr.1046
ButTo compare the therapeutic efficacy of 0.005% Latanoprost versus Xalatan® in the treatment of patients with OHT,POAG or secondary open-angle glaucoma.
MéthodesThis is a prospective, single-center, open label, three periods comparative study including 22 eyes of 13 patients. The patients from our glaucoma outpatient clinic, treated with Xalatan® monotherapy were proposed to switch their treatment to 0,005% Latanoprost for 6 weeks. After 6 weeks, they were treated again in monotherapy with Xalatan®. The IOP was measured during baseline visit (Xal 1), after 6 weeks with the generic (Lat), and again after reintroducing the Xalatan® for 6 weeks, (Xal 2). Two consecutive intraocular pressure (IOP) measures were taken during each control.
The primary end-point was the IOP variations between the brand name and the generic after the 12w. The Friedman and Wilcoxon non-parametric tests were used to assess the difference.
RésultatsThe mean age was of 66.9 ± 13.7 years. 7 men and 6 women were included in this study.
The mean IOP at baseline was 15.3 ± 2.8 mmHg with Xalatan®. The mean IOP measurements after switching to Latanoprost and crossover to Xalatan® were respectively 17.4± 3.5 mmHg mmHg and 16.4 ± 2.7 mmHg. There was an average increase of IOP of 2.1 ± 3.7 mmHg with Latanoprost. This difference was statistically significant (p=0.008).
ConclusionOur results showed an increased IOP in patients switching from Xalatan® to Latanoprost. This is of major importance in the treatment glaucoma patients.
The patients who are not accurately treated with one drop tend to have multiple drops which affects negatively the patient’s quality of life, the compliance and causes negative outcomes.
Auteur 1
NomMARINESCU
InitialesC
InstitutCliniques universitaires Saint-Luc
VilleBruxelles
Auteur 2
NomPourjavan
InitialesS
InstitutCliniques universitaires Saint-Luc
VilleBruxelles
top ^